All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @drjencaudle on TikTok · 88s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @drjencaudle's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00And I was vomiting and I'm in bed and I had my son's like,
  2. 0:03can you like play tag?
  3. 0:04And I'm like, I can't.
  4. 0:05No.
  5. 0:06And I was like, shrimbling.
  6. 0:09I lost 30 pounds so quick.
  7. 0:11I looked great and I couldn't lift my head off the billows.
  8. 0:14So what's that like?
  9. 0:17Amy Schumer has talked about her use of Ozempic in the past.
  10. 0:21Her symptoms that she describes here
  11. 0:22are the vomiting in particular.
  12. 0:24There are a number of patients who experience side effects
  13. 0:26with GLP1s such as Ozempic or lagovi.
  14. 0:31It's probably GI or gastrointestinal side effects
  15. 0:33are probably some of the most common side effects
  16. 0:36can include things like nausea or vomiting like Amy
  17. 0:39described some of my patients have had
  18. 0:41or have diarrhea, abdominal cramping, abdominal pain.
  19. 0:45And the range of those symptoms can be mild to severe.
  20. 0:49I'm not saying everyone gets them because no,
  21. 0:51not everyone gets them, but probably the most common side
  22. 0:54effect.
  23. 0:54And you certainly see are the gastrointestinal side effects.
  24. 0:58Sometimes these side effects are mitigated
  25. 0:59by reducing the dose, sort of changing the medication.
  26. 1:05Sometimes people aren't able to tolerate these medications.
  27. 1:07Everyone certainly is different.
  28. 1:10You just want to talk with your doctor
  29. 1:12and talk with your doctor about what's right for you.
  30. 1:15These medications are not right for everyone,
  31. 1:17but that's the case with any medication.
  32. 1:19You want to make sure that you meet the FDA requirements
  33. 1:23for the medication, that you're an appropriate candidate,
  34. 1:26and that you work with your doctor.

@drjencaudle's Amy Schumer GLP-1 comments, fact-checked

DrJenCaudle

TikTok creator

193.5K viewsWatch on TikTok

Quick answer

Dr. Caudle accurately characterizes GI adverse events as the most common side effect class for GLP-1 receptor agonists, consistent with data from the STEP trial program for semaglutide. She appropriately notes that symptom severity varies between patients and that dose adjustment is a legitimate clinical tool for managing tolerability. However, she does not mention that Amy Schumer's subsequent Cushing's syndrome diagnosis complicates the use of her case as a clean GLP-1 side effect example.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @drjencaudle's Amy Schumer GLP-1 comments, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@drjencaudle's Amy Schumer GLP-1 comments, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@drjencaudle's Amy Schumer GLP-1 comments, fact-checked" from DrJenCaudle. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Dr.

The reason this review is not generic is the source wording and the canonical claim label "glp1 this is what happened amyschumer drjencaudle fyp fyp f." In this clip, the useful excerpt is: "And I was vomiting and I'm in bed and I had my son's like, can you like play tag?" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Slower dose titration reduces GI side effect burden.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Dr.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Dr. Caudle accurately characterizes GI adverse events as the most common side effect class for GLP-1 receptor agonists, consistent with data from the STEP trial program for semaglutide. She appropriately notes that symptom severity varies between patients and that dose adjustment is a legitimate clinical tool for managing tolerability. However, she does not mention that Amy Schumer's subsequent Cushing's syndrome diagnosis complicates the use of her case as a clean GLP-1 side effect example.
  • In the STEP 1 trial (Wilding et al., 2021, NEJM), 44% of patients on semaglutide 2.4 mg reported nausea and 25% reported vomiting, making GI side effects the most statistically common adverse event class.
  • Slower dose titration reduces GI side effect burden. Clinical practice data supports starting at 0.25 mg weekly and titrating over months rather than weeks.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • In the STEP 1 trial (Wilding et al., 2021, NEJM), 44% of patients on semaglutide 2.4 mg reported nausea and 25% reported vomiting, making GI side effects the most statistically common adverse event class.
  • Slower dose titration reduces GI side effect burden. Clinical practice data supports starting at 0.25 mg weekly and titrating over months rather than weeks.
  • Amy Schumer later revealed a Cushing's syndrome diagnosis, which means her described symptoms cannot be cleanly attributed to Ozempic alone. Dr. Caudle did not mention this context.
  • Severe vomiting from GLP-1 medications can cause dehydration serious enough to require medical attention. Persistence of symptoms is not an indication to increase the dose.
  • FDA eligibility criteria for semaglutide (BMI 30 or above, or 27 with a weight-related comorbidity) exist as clinical thresholds, not administrative formalities. Using these drugs outside those parameters is not well-studied.
  • A 2022 meta-analysis by Shi et al. in Diabetes, Obesity and Metabolism confirmed that GI adverse events are consistently the leading reason for discontinuation across the GLP-1 drug class.
  • Not all patients experience GI side effects. Roughly half of semaglutide trial participants reported no significant nausea, so individual response genuinely varies and cannot be predicted in advance.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @drjencaudle actually say?

Dr. Jen Caudle used Amy Schumer's public account of her Ozempic experience, specifically the vomiting and debilitating fatigue that left her unable to play with her son, as a jumping-off point to explain GLP-1 side effects. Her core claim is that gastrointestinal symptoms are "probably the most common side effects" of drugs like semaglutide (Ozempic, Wegovy). She was careful to say "not everyone gets them" and pushed viewers toward their doctors rather than toward self-dosing. That framing alone puts her a cut above most GLP-1 content on TikTok.

She also noted that dose reduction or switching medications can sometimes ease those symptoms, and she flagged that FDA eligibility criteria exist for a reason. No specific doses were mentioned. No compounded alternatives were promoted. The video is essentially a side-effect explainer tied to a celebrity news hook.

Does the science back this up?

Yes, on the core claim, the evidence is solid. GI side effects are the most frequently reported adverse events in clinical trials for semaglutide and other GLP-1 receptor agonists. The SUSTAIN and STEP trial programs consistently put nausea at the top of the adverse event list.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that nausea occurred in roughly 44% of participants on 2.4 mg semaglutide, vomiting in about 25%, and diarrhea in around 30%, compared to significantly lower rates in the placebo group. A 2022 meta-analysis by Shi et al. in Diabetes, Obesity and Metabolism, pooling data across multiple GLP-1 trials, confirmed nausea and vomiting as the dominant side effect profile for this drug class. The severity spectrum Dr. Caudle describes, from mild to severe, is also accurate. Some patients in post-market surveillance have reported hospitalizations for severe dehydration secondary to vomiting, though that represents a minority. The suggestion that dose titration can reduce GI burden is also supported in the literature, particularly by the slower titration protocols introduced after early semaglutide rollout.

What did they get wrong (or right)?

Mostly right, with one notable omission. Dr. Caudle did not mention that Amy Schumer later disclosed she has Cushing's syndrome, a condition involving excess cortisol that can independently cause weight changes and fatigue. That context matters when using her case as a GLP-1 side effect illustration, since her symptoms may not have been solely medication-driven.

Beyond that omission, the medical content holds up. She avoided the common TikTok trap of implying these drugs are universally safe or trivially easy to stop. She did not overstate the celebrity case as proof of anything, she used it as an entry point. The phrase "shrimbling" in the clip is from Schumer's own words, and Dr. Caudle did not editorialize that experience into something it was not. One minor quibble: she referenced "lagovi," which appears to be a mispronunciation of Wegovy. That is a brand name issue, not a clinical one, but accuracy in drug naming matters on a platform where viewers may go searching for what they heard.

What should you actually know?

GI side effects from GLP-1 drugs are common enough that you should plan for them before starting, not be surprised by them after. The roughly 44% nausea rate from the STEP 1 trial is not a worst-case number, it is the clinical trial average. For some patients, symptoms are transient and resolve within the first few weeks. For others, like Schumer appears to have experienced, they can be severe enough to stop the medication entirely.

Dose titration protocols exist precisely to reduce this burden. Starting low and going slow is not just preference, it is the labeled approach for a reason. If your provider is skipping titration steps or dismissing GI complaints, that is worth pushing back on. Equally important: severe or persistent vomiting is not something to white-knuckle through. Dehydration can escalate quickly, and that warrants medical attention, not a higher dose. Dr. Caudle's bottom line, talk to your doctor and confirm you meet FDA criteria, is the right call. These are not supplements. They are regulated medications with real adverse event profiles.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

DrJenCaudle · TikTok creator

193.5K views on this video

This is what happened #amyschumer #drjencaudle #fyp #fypシ #fypage

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about in the step 1 trial (wilding et al., 2021, nejm),?

In the STEP 1 trial (Wilding et al., 2021, NEJM), 44% of patients on semaglutide 2.4 mg reported nausea and 25% reported vomiting, making GI side effects the most statistically common adverse event class.

What does the video say about slower dose titration reduces gi side effect burden. clinical practice?

Slower dose titration reduces GI side effect burden. Clinical practice data supports starting at 0.25 mg weekly and titrating over months rather than weeks.

What does the video say about amy schumer later revealed a cushing's syndrome diagnosis,?

Amy Schumer later revealed a Cushing's syndrome diagnosis, which means her described symptoms cannot be cleanly attributed to Ozempic alone. Dr. Caudle did not mention this context.

What does the video say about severe vomiting from glp-1 medications can cause dehydration serious enough?

Severe vomiting from GLP-1 medications can cause dehydration serious enough to require medical attention. Persistence of symptoms is not an indication to increase the dose.

What does the video say about fda eligibility criteria for semaglutide (bmi 30?

FDA eligibility criteria for semaglutide (BMI 30 or above, or 27 with a weight-related comorbidity) exist as clinical thresholds, not administrative formalities. Using these drugs outside those parameters is not well-studied.

What does the video say about a 2022 meta-analysis by shi et al. in diabetes, obesity?

A 2022 meta-analysis by Shi et al. in Diabetes, Obesity and Metabolism confirmed that GI adverse events are consistently the leading reason for discontinuation across the GLP-1 drug class.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by DrJenCaudle, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.